BSD Medical Corporation (NASDAQ: BSDM) (the Company or BSD)
announced today that Dalian Orientech Co. Ltd (Orientech), the
Companys exclusive China distributor, has ordered two BSD-2000
Hyperthermia Systems (BSD-2000). The BSD-2000 System utilizes BSDs
proprietary synchronous phased array technology to non-invasively target
therapeutic heating (hyperthermia) to certain cancerous tumors,
including those located deep within the body. Clinical studies have
shown that hyperthermia treatment can kill cancer cells directly as well
as increase the effectiveness of other cancer therapies, including
radiation therapy, for the treatment of certain tumors.
Hyperthermia cancer therapy has a strong following in China, and
Orientech controls about 65% of the market. The Orientech sales force
covers 23 provinces. After shipping the two systems, the Company will
have sold 19 BSD-2000 Hyperthermia Systems to Orientech.
Hyperthermia has been used in China for the treatment of cancer for many
years. The hyperthermia market in China has historically been supported
by Chinese manufactured systems. The market objective for BSD in China
is to continue to expand and upgrade the existing market for clinical
hyperthermia equipment to the advanced features of the BSD-2000.
About BSD Medical Corporation
BSD Medical Corporation develops, manufactures, markets and services
systems to treat cancer and benign diseases using heat therapy delivered
using focused radiofrequency (RF) and microwave energy. BSDs product
lines include both hyperthermia and ablation treatment systems. BSDs
hyperthermia cancer treatment systems, which have been in use for
several years in the United States, Europe and Asia, are used to treat
certain tumors with heat (hyperthermia) while increasing the
effectiveness of other therapies such as radiation therapy. BSDs
microwave ablation system has been developed as a stand-alone therapy to
employ precision-guided microwave energy to ablate (destroy) soft
tissue. The Company has developed extensive intellectual property,
multiple products in the market and well established distribution in the
United States, Europe and Asia. Certain of the Companys products have
received regulatory approvals and clearances in the United States,
Europe and China. The BSD-2000 is restricted to investigational use in
the US. For further information visit BSD Medicals website at www.BSDMedical.com.
Statements contained in this press release that are not historical facts
are forward-looking statements, as defined in the Private Securities
Litigation Reform Act of 1995. All forward-looking statements are
subject to risks and uncertainties detailed in the Companys filings
with the Securities and Exchange Commission. These forward-looking
statements speak only as of the date on which such statements are made,
and the Company undertakes no obligation to update such statements to
reflect events or circumstances arising after such date.

Source: Business Wire